Pamidronate (Aredia)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 10/31/1991: Initial FDA approval

Also known as

  • Generic name: pamidronate disodium omega
  • Brand name: Aredia, Padium, Pamisol


  1. 1.0 1.1 Pamidronate (Aredia) package insert
  2. Pamidronate (Aredia) package insert (locally hosted backup)
  3. Pamidronate manufacturer's website
  4. Pamidronate (Aredia) patient drug information (UpToDate)